Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-23-015749
Filing Date
2023-04-28
Accepted
2023-04-28 16:00:45
Documents
14
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A onct-20221231.htm   iXBRL 10-K/A 952209
2 EX-31.3 onct-ex31_3.htm EX-31 8118
3 EX-31.4 onct-ex31_4.htm EX-31 8115
  Complete submission text file 0000950170-23-015749.txt   1231366

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT onct-20221231_pre.xml EX-101.PRE 18115
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT onct-20221231.xsd EX-101.SCH 2671
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT onct-20221231_lab.xml EX-101.LAB 29425
8 EXTRACTED XBRL INSTANCE DOCUMENT onct-20221231_htm.xml XML 11282
Mailing Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

EIN.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-50549 | Film No.: 23865680
SIC: 2834 Pharmaceutical Preparations